AT1 FY21 - General Discussion + FA, page-16

No worries, happy to help, lets keep an joint eye out, see what we can find + collate over time.
----------------
I have been looking at any prod dev material since June'20- the data/news publicly available is pretty slim for now; cannot find any other companies that have mentioned or brought up AT1 devices/collaboration in side comments, tweets, Q&A etc - which is a positive thing because AT1 is keeping its future dev pipeline well guarded, as it should. I also have been reading on the side new POCT tech dev info, there are several methods brewing globally, including 3D printed nanotech strips, multiplex tests combining 2-4-6 diseases types etc Just can't see which ones might connect to AT1 yet.

1) we know the base device evolution planned from AT1 presentation pics and broad value adds like 'digital health, cloud data upload, eReader capability etc
+
2) original FebriDx test ann mentioned that US trials (current underway) were planned with an AT1 digital device (Elion? auto-AMR test data upload+ AI driven analysis? unknown, nothing mentioned specific anywhere)
+
3) CEO has mentioned 'inbound enquiries from other test dev for next gen platforms' + wants to keep AT1 on cutting edge of POCTs
- eg: FY20 Q&A he mentioned lateral flow tech was 20yr+ old tech....though everyone uses it today, he didn't want to keep building devices that one day would/could be obsolete....he wants AT1 to continue disrupting itself. Mentioned they were in active discussions with 2x start-up US companies that were developing new approach for POCT testing